Telitacicept for systemic lupus erythematosus: protocol of a systematic review and meta-analysis
Introduction Systemic lupus erythematosus (SLE) is a chronic and complex multisystem autoimmune disease with high mortality. Telitacicept is a new strategy for the treatment of SLE, inhibiting the maturity, proliferation and differentiation of B cells, and thus, reduces disease activity. However, th...
Saved in:
| Main Authors: | Xin Yu, Jiawei Zhang, Xiangge Ren, Peidong Zhao, Wensheng Zhai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/7/e090646.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis
by: Shenglan Gao, et al.
Published: (2025-01-01) -
Efficacy and safety of acupuncture for IgA vasculitis abdominal pain: protocol for a systematic review and meta-analysis
by: Xiangge Ren, et al.
Published: (2025-07-01) -
Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus
by: Xiaowei Chen, et al.
Published: (2025-06-01) -
Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study
by: Min-Ying Liu, et al.
Published: (2025-07-01) -
Recurrent Palpitation in a Young Man with Systemic Lupus Erythematosus Undergoing Belimumab with Resolution After Switching to Telitacicept
by: Yanfen Mai, et al.
Published: (2024-01-01)